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Pyrazinamide (PZA) has become an essential component of current 6-month regimens for therapy
of tuberculosis. Susceptible strains of tubercle bacilliconvert PZA to pyrazinoic acid (POA)through
pyrazinamidase (PZase), which resistant strains and Mycobacterium bovis bacilleCalmette-Guerin
lack. PZA susceptibility results obtained in cultured human macrophages were compared with
those in the broth BACTEC system with 7H12 medium at pH 6.0 for strains known to bePZase-
positive or -negative. Although added PDA was unable to inhibit tubercle bacilli in cultured
macrophages, it was able to inhibit them at very high concentrations in the BACTEC broth. In-
tracellularly formed PDA would not be able to escape from the macrophage, and therefore would
accumulate sufficiently to lower pH to toxic levels for tubercle bacilli. The results suggest that
the cultured macrophages contribute actively or passively to the effectiveness of PZA, such as
through the proposed mechanism of low pH generated by PZase in the phagolysosomes.
In 1982 the World Health Organization estimated that 4-5
million new highly infectious, smear-positive cases of pul-
monary infection with Mycobacterium tuberculosis occur
worldwide every year [1].
Although pyrazinamide (PZA) was synthesized before 1940
[2], its antituberculous activity was not recognized until the
early 1950s [3]. Currently, PZA is one of the essential drugs
in the modern chemotherapy of tuberculosis [4,5]. The in-
clusion of PZA in treatment regimens has made possible the
shortening of therapy to 6 months [6, 7]. Analyzing data from
several clinical trials with different regimens, Mitchison [8]
hypothesized that antituberculous drug activity is influenced
by different mycobacterial populations within lesions. The
populations are defined by the metabolic activityof the tubercle
bacilli and the pH of their microenvironment.
Konno et aI. [9] found a correlation between pyrazinami-
dase (PZase) activity and susceptibility of Mycobacterium
bovis and M. tuberculosis to PZA. PZA-susceptible strains
of M. tuberculosis deaminate PZA to pyrazinoic acid (POA),
whereas PZA-resistant strains of M. tuberculosis and the nat-
urally resistant M. bovis strains are not able to convert PZA
to POA.
Recently, a simple radiometric method wasreported for sus-
ceptibility testing of M. tuberculosis against PZA at pH 6.0
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[10]. This BACTEC method and the in vitro system of cul-
tured human blood macrophages [11] made possible more
definitive experiments with PZA.
The aims of the present study were to ascertain whether
cultured human blood macrophages could be used to study
the interaction ofPZA with different clinical strains of tuber-
cle bacilli, to compare those results with the minimum in-
hibitory concentrations (MICs) determined in the BACTEC
system, and to study the mechanism of PZA action in both
systems.
Materials and Methods
Human subjects. Blood monocytes [12] from a healthy tubercu-
lin purified protein derivative (PPD)-negative white woman and from
a healthy PPD-positive white man, both 38 years old, were used.
Tuberclebacilli. Nine mycobacterial isolates were used: four clin-
ical M. tuberculosis isolates from different patients (stock culture
numbers TB186, TB189,TB206, and TB213), three laboratory strains
(Erdman, H37, and PZA-resistant [TMC31l]), and 2 different sources
of M. bovis bacille Calmette-Guerin (BCG): Paris 1173 derivative
(BCG-French) and macrophage-passaged BCG originally of the Tice
strain (BCG-WWLI) [13]. All three laboratory strains and TB213
were fully susceptible to isoniazid, rifampin, ethambutol, and strep-
tomycin. TB186 was monoresistant to rifampin and TB189 to isonia-
zid, and TB206 was resistant to both. The isolates were prepared
in batches and stored in single-use aliquots at -90°C until being
used to infect the macrophages. The preparation and use ofthe Erd-
man strain was as described [11], except that the inoculum for the
macrophages was reduced to "-'100-300 colony-forming units
(cfu)/ml. The others were prepared similarly.
Macrophage cultures. The human monocytes used were adher-
ent cells from peripheral blood cultured in monolayers with "-'5 x
105 cells in each of three spots on disposable plastic Petri dishes
(35 mm diameter). Each dish contained 1.5ml of RPMI 1640 medium
supplemented with 1% unheated AB serum and kept at pH 7.2 in
7.5% CO~. The monocytes were cultured for 7 days, and the result-
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ing macrophages were infected for 30 min at 37°C with ultrasoni-
cally dispersed, log-phasemycobacteria. After infection,the monocytes
were washed twice with unsupplemented, prewarmed RPMI and then
incubated for 7 more days (for M. bovis BCG strains, 10 days) in
complete RPMI medium with or without the tested drugs as described
below. The controls were done in duplicate or triplicate. In one ex-
periment, media from 7-day-old macrophage cultures without drugs
were filter-sterilized and used again ("conditioned medium").
Counts ofbacilli. Counts were made using samples of Petri dish
cultures taken at 0 (immediately after infection), 4, and 7 days (un-
less otherwise stated) as described [12]. Briefly, medium from each
plate was drawn off and discarded. The plates were rinsed twice with
7H9 liquid medium (Difco, Detroit) and frozen at -90°C. When
all plates were collected, each was thawed and lysed with sodium
dodecyl sulfate solution. The lysate was neutralized with bovine se-
rum albumin, sonicated for 10 s, and diluted in IO-foldsteps in 7H9
medium. Samples were plated in quintuplet on 7HIO agar.
After 2 weeks of incubation, colonies of mycobacteria on the 7HIO
agar plates were counted, and from these counts the numbers of cul-
turable mycobacteria per 1 x lOS macrophages was calculated [11].
The values reported were means of five values each. Standard er-
rors of means usually were <10% of the means; these values are
not shown in the figures, because the data are plotted semilogarith-
mically.
We used three terms to describe the effect of the drugs: bacteri-
ostatic, no change in number of viable bacilli over time compared
with the initial inoculum; inhibitory, increased number of viable
bacilli compared with the initial inoculum but fewer than the con-
trol; and bactericidal, decreased number of viable bacilli over time
compared with the initial inoculum.
Drugs. Pyrazinamide (Sigma Chemical, St. Louis) and pyra-
zinoic acid (Aldrich Chemical, Milwaukee) were dissolved and
diluted in the RPMI culture medium to the required concentrations
of PZA (25-800 mg/l) and POA (12.5-200 mg/l) before steriliza-
tion by membrane filtration.
MIC determinations in the BACTEC system [10]. Isolates were
cultured in regular 7H12 broth (Becton Dickinson Diagnostic In-
strument Systems, Towson, MD) supplemented with polyoxyethyl-
ene stearate (POES) at 36°C. The growth index was recorded daily
in the BACTEC system until it was >300. Then, 0.1 ml of this cul-
ture was transferred into a special7H12 broth (4 ml, pH 6.0; Becton
Dickinson) that contained 25, 50, and 100 mg/l of PZA after addi-
tion of 0.1 ml of the appropriate stock solution of PZA with POES.
This set included controls at pH 6.8 and pH 6.0. Isolates resistant
to 100 mg/l PZA were retested against 25-100 and 200-6400 mg/1.
The growth in all vials was recorded daily until the growth index
in the control vial (pH 6.0) reached ~200. The MIC was defined
as the lowest concentration that produced ~IO% ofthe growth index
compared with the control vial.
Killing curves. Since large amounts of PZA are not dissolved
easily, 2 ml ofthe special 7H12 broth (pH 6.0) was used for prepara-
tion of the stock solutions of PZA. The other 2 ml of broth was in-
oculated with the Erdman strain and incubated. At day 2, the growth
index was 1"\)60, and 2 ml of broth (with or without PZA) was added
to all vials, resulting in a final concentration of 0, 25, 100, 400, or
1600 mg/l PZA. This set was used in duplicate (10 vials). Immedi-
ately after the 2 ml of broth was added (day 0), an aliquot of 0.1
ml was taken and diluted with regular 7H9 broth in a microtiter plate.
From appropriate dilutions, 20 1-'1 of the broth was spotted in quin-
tuplicate onto a 7HIO agar plate, and after 2 weeks of incubation
the colonies were counted and the colony-forming units per milliliter
calculated. To minimize the loss of broth during the experiment,
an aliquot was taken only every other day until day 8. All vials were
measured for 14C02 production in the BACTEC system.
P'Znse activity. PZase activity was determined by the method de-
scribed by Wayne [14] with heavily grown cultures on Lowenstein-
Jensen slants. Isolates without PZase activity at day 7 were tested
twice before being considered negative.
Determination ofpH ofbroths. The pH was determined with a
digital pH meter (Corning Model 130 with Semi-Micro Combina-
tion Probe, No. 476541).
Results
Effect ofPZA against different M. tuberculosis isolates in
macrophages. The virulent Erdman strain was used with ev-
ery batch of human macrophages as an internal standard. Dur-
ing the 7-day period, the tubercle bacilli multiplied by a factor
of 37. PZA was inhibitory at the lowest concentration tested
Table 1. Growth kinetics of tested Mycobacterium tuberculosis isolates in cultured human macrophages with and without pyrazinamide
(PZA) compared with BACTEC minimum inhibitory concentrations (MICs) and pyrazinamidase (PZase) activity.
Cultured human macrophages
cfu ratio* in presence of PZA at concentration (mg/l) % inhibition at BACTEC MIC
day 7 by ofPZA
Isolate 0 50 200 800 800 mg/l PZA (mg/l) PZase activity
Laboratory
Erdman 37 3.2 2.8 1.3 96.5 50 Positive
H37 35 5.2 2.5 1.2 96.6 25 Positive
TMC311 30 21.0 31.0 33.0 -10 >6400 Negative
Clinical
TB186 146 4.4 2.2 -1.0 99.3 3200 Positive
TB189 87 7.4 0.7 0.1 99.9 <25 Positive
TB206 16 11.9 5.1 2.5 84.4 400 Weakly positive
TB213 19 3.2 0.9 0.4 97.9 <25 Positive
* Colony-forming units (efu) day 7:efu day O.
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Figure 1. Growth of Erdman strain of Mycobacterium tuberculosis tested with and without pyrazinamide (PZA) in cultured human mac-
rophages under different media: A, traditional macrophage system; B, initial amounts of PZA added daily; C, culture medium with and
without PZA replaced daily with fresh medium and constant drug concentrations; D, culture medium with and without PZA replaced
daily with conditioned medium.
(25 j.tglml). However,even at 800 j.tg/ml the drug only slowed
intracellular bacillary growth and was not bactericidal. In the
absence of PZA the resistant isolate TB206 multiplied 16-
fold and the susceptible isolate TB189 multiplied 87-foldcom-
pared with the initial number of bacilli. At 800 j.tg/ml, the
resistant isolate still grew 2.5-fold, whereas there was a
marked bactericidal decrease in numbers of TB189 bacilli.
The growth kinetics of all tested M. tuberculosis isolates are
summarized in table 1. With increasing PZA concentrations,
growth of all except the PZA-resistant TMC311 was dimin-
ished.
Ineffectiveness of PZA against different M. bovis BeG
strains. During the 10 days of observation, the two BCG
strains showed no significant difference between the control
and the highest concentration of PZA (400 mg/l) tested.
Effects ofadding PZA to the macrophage media throughout
the period ofinfection. In the four experiments illustrated
in figure 1, the Erdman strain grew more between days 4 and
7 than between days 0 and 4. This suggested that PZA might
be losing effectiveness by being metabolized. In the second
experiment, the same system was used but additional drug
equal to the initial concentration was added daily to the cul-
ture medium; for example, 800 became 5600 mg/l by day 7
(figure 1B). Despite the presence of these large amounts of
PZA, no significant decrease in tubercle bacilli was observed
during the first 4 days, and only minimal decline by day 7.
Experiments were also done in which the medium was
replaced instead of adding PZA daily (figure 1C)or in which
medium with PZA was taken from cultures of infected mac-
rophages at the end of day 7 of culture and used on freshly
infected macrophages (figure 10). In both instances, the PZA
was slightly more inhibitory than PZA added just once at the
beginning of the experiment or added daily, indicating that
its relative loss of effectiveness with time after infection and
addition was not due to its breakdown.
Earlykinetics ofErdman strain in macrophage cultures. If
the change in effectiveness of PZA with time after infection
was not due to inactivation of PZA, it might have been due
to a change in characteristics of the infecting tubercle bacilli,
for example, emergence of resistant clones. This was tested
by counts at 8- to 12-h intervals after a single addition of 100
or 400 mg/l PZA. After an initial loss of almost 50% of the
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with those in infected macrophages. Both release of 14C02
and counts were determined. Figure 4A shows inhibition of
the Erdman strain proportional to PZA concentration up to
400 mg/I. The inhibition was bacteriostatic, as shown by
counts of colony-forming units per milliliter (figure 4B).
Action of POA in the BACTEC system against Erdman or
TMC311 strain. The ineffectiveness of POA against tuber-
cle bacilli in macrophages might be due to its inability to en-
ter the macrophage. Ifso, it might be effective if used directly
in 7H12 broth. Also, if it is the effector molecule of PZA [9],
it should be able to inhibit PZase-negative tubercle bacilli as
readily as it does PZase-producing bacilli. These hypotheses
were tested with the Erdman strain (PZA-susceptible) and
TMC311 (PZA-resistant, PZase-negative). Figure 5 shows
that high concentrations of POA (~400 mg/l) inhibited both
strains similarly and in proportion to the concentration of the
drug through the highest concentration (1600 mg/I) used, ei-
ther at pH 6.0 or 6.8.
The ability of POA to inhibit tubercle bacilli in 7H12 broth
was greater at pH 6.0 than at pH 6.8. This suggested a connec-
tion between pH and inhibition. Since tubercle bacilli are
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Figure 2. Growth ofErdmanstrainofMycobacterium tuberculo-
sis testedwith and withoutpyrazinamide (PZA) in cultured human




Figure 3. Growth ofErdmanstrainof Mycobacterium tuberculo-
sis tested with and withoutpyrazinoicacid (POA) or pyrazinamide









viable tubercle bacilli within 16 h, a period of growth inde-
pendent ofPZA concentration followed (figure 2). Within the
next 24 h, there was again a decrease in tubercle bacilli in
the presence ofPZA. At day 3 the bacilli again began to mul-
tiply.
Action ofPOA in macrophage cultures. As shown in figure
3, POA was not significantly protective at either 50 or 200 1000 '-----'------'-----'_...L..-.--'------'-_'-----l----l..---J._-L--L------L---.J
mg/I, compared with 50 mg/I PZA against the Erdman strain. 0 2 3 4 5 6 7 8 9 10 11 12 13 14
PZA MICs in the BACTEC system. The MICs of PZA forw,www",,> Days After Adding PZA
seven M. tuberculosis isolates varied from <25 to >6400 mg/I Figure 4. Growth kinetics of Erdman strain of Mycobacterium
(table 1). One of the BCG strains had an MIC of 6400 and tuberculosiscultured inspecial7H12 brothwithandwithout pyrazina-
the other, >6400 mg/I. mide(PZA): A: expre~sed as g~o~~h indexin the BACTEC system;
D'7_ •• All M b losi I b B, colony-forming units per milliliter,
rcase activity. . tu ercu OSiS ISO ates ut one
(TMC311) showed PZase activity (table 1). Isolate TB206 was
consistently weakly positive. The two M. bovis BCG strains
were negative.
Effect of PZA against Erdman strain in the BACTEC sys-
tem. The Erdman strain was tested for comparison of results
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Figure 5. Growth kinetics with and without pyrazinoic acid (POA) of Erdman (pyrazinamide [PZA]-susceptible) strain (A, C) and PZA-
resistant strain TMC311 (B, D) cultured in special (pH 6.0) and regular (pH 6.8) 7H12 broth, respectively, and expressed as growth index
in the BACTEC system.
pH8.----'-----------------------.,
Discussion
A pulmonary tuberculous lesion begins when an inhaled
tubercle bacillus is ingested by a resident alveolar macrophage.
If this macrophage is incapable of-killing the tubercle bacil-
lus, the bacterium replicates, and its progeny eventually lyse
the macrophage. Bacilli released from the disintegrated mac-
rophage are then taken up by other alveolar macrophages,
which in turn are also lysed. The products of cell and bac-
terial debris are chemoattractants for circulating monocytes
and polymorphs, and in time the monocytes become the pri-
mary cell type at the site of the lesion [16].
The mechanisms by which macrophages attempt to kill
mycobacteria and the ways by which mycobacteria avoid be-
ing killed have been reviewed by Lowrie [16]. The main prob-
lem faced in the study of macrophage-killing mechanisms in
a host is the complexity of this system.
PZA was synthesizedbefore 1940 [2], but its antituberculous
activity was not recognized until the early 1950s [3]. The in-
clusion of PZA in treatment regimens has made possible the
shortening of therapy to 6 months [6, 7], and at present PZA
is the third most important drug in the modern chemotherapy

















inhibited by low pH alone [15], the pH values of media con-
taining the various concentrations of PDA weremeasured,
The larger, inhibitory concentrations of PDA caused sig-
nificant decreases in pH (figure 6), and these were propor-




Figure 6. pH values of regular (pH 6.8) and special (pH 6.0) 7H12
broth with different amounts of pyrazinoic acid (POA).
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uptake and biotransformation of PZA has been studied only
sporadically. There is still a gap in our knowledgeof how PZA
actually works [17, 18].
Because there are individual variations in uptake and kill-
ing of tubercle bacilli [13]by macrophages, we used the same
monocyte donor during the experiments reported here. As an
internal standard, the virulent Erdman strain M. tuberculo-
sis was used with every batch of macrophages. Our results
showed a bacteriostatic effect of PZA on the Erdman strain,
confirming recently published data [19, 20].
The effectiveness of PZA varied widely among mycobacterial
strains. As expected, it was ineffective either in the BACTEC
system or in cultured macrophages against PZase-negative
M. tuberculosis and M. bovis BCG. In experiments to deter-
mine whether PZA is bactericidal or bacteriostatic, growth
of M. tuberculosis in 7HI2 broth media provided no evidence
for killing by PZA within I week of observation. PZA in broth
appeared to be bacteriostatic at best (figure 4), whereas POA
at high concentrations completely stopped 14COZ production
by tubercle bacilli. In cultured macrophages infected with
PZA-susceptible strains, however, PZA only slowed bacterial
growth unless used in large concentrations not clinically
achievable. This confirms our earlier observations [19].
PZA acts synergistically with other antituberculous drugs
to kill tubercle bacilli. We have in fact observed this with chlo-
roquine [21]. McDermott and Tompsett [22] recognized that
PZA is active only at an acid pH. When PZA is bactericidal
in vitro, the pH it requires is only slightly above the pH lethal
for tubercle bacilli.
Since the growth of the controls varied considerably (table
I), we calculated the percentage of inhibition to enable com-
parison of PZA activity within the macrophages against the
different isolates. Those susceptible were 96.5%-99..9 % in-
hibited, whereas all but one (TBI86) of the resistant ones were
less so. The anomalous behavior of TBI86 maybe due to meta-
bolic heterogeneity among progeny. On the basis of the per-
centage of inhibition, there was a good correlation between
the MICs determined in vitro and the activity of PZA within
human macrophages.
A simple method is available for qualitative determination
ofPZase activity [14]. With this method, several groups have
confirmed a correlation between PZase activity and suscepti-
bility to PZA [23-25]. In this study, we used two isolates with
discrepant results: TB206 had weak activity, and TBI86 was
recognized already as an exception. McClatchy et al. [23] de-
scribed an isolate that produced PZase but was not propor-
tionally susceptible to PZA. This heterogenous strain showed
50 % resistant colonies on subculture. Butler and Kilburn [26]
worked with H37Rv mutants and found no direct correlation
between loss of PZase activity and the level of PZA resis-
tance. So far, however, only a few strains have been found
that produce PZase but are PZA-resistant.
The metabolism of PZA in humans is well understood [27].
Twoof three major metabolites of PZA were identified in 1972
as POAand 5-hydroxy-POA[28]. 5-hydroxy-PZA, the recently
recognized third metabolite [29], is produced by the direct
action of xanthine oxidase on PZA [30]. Lacroix et at. [31]
studied the pharmacokinetics of PZA and its metabolites in
healthy people and proposed the following metabolic path-
ways: major (PZA is deaminated to POA, which is hydrox-
ylated to 5-0H-POA) or minor (PZA is first hydroxylated to
5-0H-PZA and then deaminated to 5-0H-POA). If certain
strains of tubercle bacilli could also metabolize PZA by differ-
ent pathways, it might explain the occasional discrepant results
between PZase activity and susceptibility to PZA.
As regards mode of action, the theory that PZA inhibits
tubercle bacilli via POA produced by bacterial PZase is con-
sistent with our findings. PZase-negative tubercle bacilli were
resistant to PZA in both infected cultured macrophages and
the BACTEC system. Although POA was unable to inhibit
tubercle bacilli in cultured macrophages, it was able to in-
hibit them at high concentrations in the BACTEC system.
PDA's ability ~o inhibit tubercle bacilli in the BACTEC sys-
tem was proportional to its concentration and to a decrease
in pH that in itself may be inhibitory (figure 6). It is possible,
therefore, that PZA inhibits tubercle bacilli in cultured mac-
rophages physically rather than biochemically. After enter-
ing infected macrophages, PZA would be converted to PDA
by tubercle bacilli and would accumulate in the phagolyso-
somes, thereby lowering the microenvironmental pH.
The results shown in figure 2 support the hypothesis [19]
that the antituberculosis action ofPZA is controlled via a self-
modulating feedback loop. In the acidic (pH 5.2) environment
of the host'sphagolysosomes [32, 33], PZase in tubercle bacilli
will convert PZA to POA. IfPOA cannot reach tubercle bacilli
sequestered in the macrophage, as our results suggest, it may
be that POA formed intracellularly cannot escape from the
macrophage. This would result in accumulation of POA and
a drop in pH sufficient to be toxic for tubercle bacilli. At the
same time, however, mycobacterial metabolism produces am-
monia, which can increase the intracellular pH [34], and, to
a certain extent, neutralize the acidity ofPOA. M. tuberculo-
sis-derived protein has an effect similar to that of ammonia
[35]. Either mechanism would allow resumed growth of the
tubercle bacilli within the macrophage.
The comparative activity of PZA and PDA against tuber-
cle bacilli in the infected macrophage and broth BACTEC sys-
tems provides further insights into the possible mechanism
ofPZA's clinical effectiveness versus M. tuberculosis. Activ-
ity of PZA or PDA in the BACTEC system is not dependent
on drug penetration, as it is in the macrophage model. PDA
was active in the BACTEC system but not in cultured macro-
phages, whereas PZA, which can readily enter cultured mac-
rophages, was active in both. Tubercle bacilli were not killed
in the BACTECsystem, and inhibitionby PZA required higher
concentrations in the BACTEC systemthan in cultured mac-
rophages. These results suggest that the cultured macrophage
must contribute actively or passively to effectiveness of PZA,
JID 1990;162 (July) Pyrazinamide Activity 207
such as through the proposed mechanism of low pH gener-
ated by PZase in the phagolysosomes. A purely in vitro test
such as the BACTEC system can serve as a convenient tool
for evaluating antimycobacterial drugs, but the cultured mac-
rophage system may more closely approximate in vivo reality.
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